Inhibitor of apoptosis protein (IAP) profiling in experimental autoimmune encephalomyelitis (EAE) implicates increased XIAP in T lymphocytes

Craig S. Moore; Andrea L.O. Hebb; George S. Robertson

doi:10.1016/j.jneuroim.2007.10.022

Inhibitor of apoptosis protein (IAP) profiling in experimental autoimmune encephalomyelitis (EAE) implicates increased XIAP in T lymphocytes

Craig S. Moore, Andrea L.O. Hebb, George S. Robertson

Medicine

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

In multiple sclerosis (MS) and its widely accepted animal model, experimental autoimmune encephalomyelitis (EAE), the failure of autoreactive immune cells to undergo apoptosis is thought to contribute to CNS tissue damage and disease progression. Promoting apoptosis of myelin-reactive immune cells in diseases such as MS, may delay disease progression and decrease the frequency and severity of relapses. X-linked inhibitor of apoptosis (XIAP) is a potent anti-apoptotic protein that inhibits intrinsic, extrinsic, and c-Jun amino-terminal kinase mediated apoptosis and was the only member of the inhibitor of apoptosis (IAP) family upregulated in whole blood from EAE mice. Similar increases in XIAP were also observed in both peripheral and encephalitogenic T lymphocytes. Increased XIAP expression in T cells within areas of demyelination in the CNS suggests that XIAP may be enhancing cell survival and thereby contributing to disease pathology.

Original language	English
Pages (from-to)	94-105
Number of pages	12
Journal	Journal of Neuroimmunology
Volume	193
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jneuroim.2007.10.022
Publication status	Published - Jan 2008

Bibliographical note

Funding Information:
The authors would like to thank the Merck Frosst Centre for Therapeutic Research and D.W. Nicholson for the generation and donation of the anti-caspase cleaved spectrin antibody. This study was supported by Genome Canada and Aegera Therapeutics Inc. CSM holds a research studentship from the Multiple Sclerosis Society of Canada. ALOH holds a post-doctoral fellowship from the Multiple Sclerosis Society of Canada.

ASJC Scopus Subject Areas

Immunology and Allergy
Immunology
Neurology
Clinical Neurology

Access to Document

10.1016/j.jneuroim.2007.10.022

Cite this

@article{193daf0ce7e14a239d9744a0767daaaf,

title = "Inhibitor of apoptosis protein (IAP) profiling in experimental autoimmune encephalomyelitis (EAE) implicates increased XIAP in T lymphocytes",

abstract = "In multiple sclerosis (MS) and its widely accepted animal model, experimental autoimmune encephalomyelitis (EAE), the failure of autoreactive immune cells to undergo apoptosis is thought to contribute to CNS tissue damage and disease progression. Promoting apoptosis of myelin-reactive immune cells in diseases such as MS, may delay disease progression and decrease the frequency and severity of relapses. X-linked inhibitor of apoptosis (XIAP) is a potent anti-apoptotic protein that inhibits intrinsic, extrinsic, and c-Jun amino-terminal kinase mediated apoptosis and was the only member of the inhibitor of apoptosis (IAP) family upregulated in whole blood from EAE mice. Similar increases in XIAP were also observed in both peripheral and encephalitogenic T lymphocytes. Increased XIAP expression in T cells within areas of demyelination in the CNS suggests that XIAP may be enhancing cell survival and thereby contributing to disease pathology.",

author = "Moore, {Craig S.} and Hebb, {Andrea L.O.} and Robertson, {George S.}",

note = "Funding Information: The authors would like to thank the Merck Frosst Centre for Therapeutic Research and D.W. Nicholson for the generation and donation of the anti-caspase cleaved spectrin antibody. This study was supported by Genome Canada and Aegera Therapeutics Inc. CSM holds a research studentship from the Multiple Sclerosis Society of Canada. ALOH holds a post-doctoral fellowship from the Multiple Sclerosis Society of Canada. ",

year = "2008",

month = jan,

doi = "10.1016/j.jneuroim.2007.10.022",

language = "English",

volume = "193",

pages = "94--105",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Inhibitor of apoptosis protein (IAP) profiling in experimental autoimmune encephalomyelitis (EAE) implicates increased XIAP in T lymphocytes

AU - Moore, Craig S.

AU - Hebb, Andrea L.O.

AU - Robertson, George S.

N1 - Funding Information: The authors would like to thank the Merck Frosst Centre for Therapeutic Research and D.W. Nicholson for the generation and donation of the anti-caspase cleaved spectrin antibody. This study was supported by Genome Canada and Aegera Therapeutics Inc. CSM holds a research studentship from the Multiple Sclerosis Society of Canada. ALOH holds a post-doctoral fellowship from the Multiple Sclerosis Society of Canada.

PY - 2008/1

Y1 - 2008/1

N2 - In multiple sclerosis (MS) and its widely accepted animal model, experimental autoimmune encephalomyelitis (EAE), the failure of autoreactive immune cells to undergo apoptosis is thought to contribute to CNS tissue damage and disease progression. Promoting apoptosis of myelin-reactive immune cells in diseases such as MS, may delay disease progression and decrease the frequency and severity of relapses. X-linked inhibitor of apoptosis (XIAP) is a potent anti-apoptotic protein that inhibits intrinsic, extrinsic, and c-Jun amino-terminal kinase mediated apoptosis and was the only member of the inhibitor of apoptosis (IAP) family upregulated in whole blood from EAE mice. Similar increases in XIAP were also observed in both peripheral and encephalitogenic T lymphocytes. Increased XIAP expression in T cells within areas of demyelination in the CNS suggests that XIAP may be enhancing cell survival and thereby contributing to disease pathology.

AB - In multiple sclerosis (MS) and its widely accepted animal model, experimental autoimmune encephalomyelitis (EAE), the failure of autoreactive immune cells to undergo apoptosis is thought to contribute to CNS tissue damage and disease progression. Promoting apoptosis of myelin-reactive immune cells in diseases such as MS, may delay disease progression and decrease the frequency and severity of relapses. X-linked inhibitor of apoptosis (XIAP) is a potent anti-apoptotic protein that inhibits intrinsic, extrinsic, and c-Jun amino-terminal kinase mediated apoptosis and was the only member of the inhibitor of apoptosis (IAP) family upregulated in whole blood from EAE mice. Similar increases in XIAP were also observed in both peripheral and encephalitogenic T lymphocytes. Increased XIAP expression in T cells within areas of demyelination in the CNS suggests that XIAP may be enhancing cell survival and thereby contributing to disease pathology.

UR - http://www.scopus.com/inward/record.url?scp=37749024033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37749024033&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2007.10.022

DO - 10.1016/j.jneuroim.2007.10.022

M3 - Article

C2 - 18055022

AN - SCOPUS:37749024033

SN - 0165-5728

VL - 193

SP - 94

EP - 105

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

IS - 1-2

ER -

Inhibitor of apoptosis protein (IAP) profiling in experimental autoimmune encephalomyelitis (EAE) implicates increased XIAP in T lymphocytes

Abstract

Bibliographical note

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this